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The Iowa Department of Public Health 
(IDPH), Bureau of Immunization and 
Tuberculosis is extending a temporary, 
limited waiver of the provision of 641 
Iowa Administrative Code (IAC) 7.4(1) 
requiring administration of the final dose 
of Haemophilus influenzae Type b 
(Hib) vaccine on or after 12 months 
of age.  
 
This waiver was effective December 
19, 2007, and is hereby extended to 
June 30, 2010. This waiver will 
prevent children from being 
excluded from licensed child care 
centers because of their inability to 
obtain the final dose of Hib vaccine 
on or after 12 months of age.  
Issuance of this waiver is necessary 
in light of the past nationwide shortage 
of the Hib vaccine.  
 
On December 19, 2007, the Centers for 
Disease Control and Prevention (CDC), 
in consultation with the Advisory 
Committee on Immunization Practices 
(ACIP), the American Academy of 
Family Physicians, and the American 
Academy of Pediatrics, published a 
recommendation in the Morbidity and 
Mortality Weekly Report (MMWR) that 
directed providers to temporarily defer 
the routine Hib vaccine booster dose 
administered at age 12-15 months 
except to children in specific 
high-risk groups.  
 
Beginning in July 2009, 
CDC recommended 
reinstatement of the booster 
dose and limited catch up 
with currently available 
products. Although supply 
was sufficient to reinstate 
the booster dose and begin 
catch-up vaccination, there 
was not enough supply to 
support the immediate recall of all 
children with deferred booster doses.   
 
At this time, supply of Hib vaccine is 
adequate to fully reinstate catch-up 
programs.  Health care providers are 
encouraged to perform active recall 
for those children still needing a final 
dose of Hib vaccine.  Continued on page 2.  
 
unization Program
Rotavirus Vaccine Recall  
Recommendation to Temporarily 
Suspend Usage of GlaxoSmithKline 
(GSK) Rotarix (Rotavirus) Vaccine:  
The U.S. Food and Drug Administration 
(FDA) has learned that DNA from 
porcine circovirus type 1 (PCV1), a virus 
not known to cause disease in humans 
or animals, is present in the Rotarix 
vaccine made by GSK. Patients who 
received this vaccine do not need to take 
further action.   
 
FDA is recommending that health care 
practitioners temporarily suspend usage 
of the Rotarix vaccine for rotavirus 
immunization in the United States while 
the FDA convenes a committee of 
experts to review information 
surrounding this issue.   
 
Health care providers should maintain 
product in accordance with the package 
insert until further review and direction 
from the FDA.  
 
For additional information please visit the 
U.S. Food and Drug Administration Web 
site or the CDC Health Alert Network 
Web site.  
Call the IRIS  
Help Desk at 
 1-800-374-3958  
for Enrollment Details or 
IRIS Questions. 
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Continued from page 1 
Hib Vaccine and VFC Providers  
Beginning April 1, 2010, the CDC 
removed the Hib vaccine allocation 
for the Iowa Vaccines for Children 
(VFC) Program, which will allow for 
the routine ordering of all Hib-
containing vaccines.  
 
The Hib shortage may have 
required health care providers to 
switch to other Hib-containing 
vaccines to complete the primary 
Hib series.  
 
It is important when placing vaccine 
orders of Hib-containing vaccine to 
consider current inventory of both 
single antigen and combination Hib 
On February 19, 2010, the FDA 
licensed a second meningococcal 
conjugate vaccine, Menveo 
(MenACWY-CRM), manufactured by 
Novartis Vaccines. 
 
Menveo will follow the same ACIP 
recommendations as the previously 
licensed meningococcal vaccine, 
Menactra, manufactured by Sanofi 
Pasteur.  Menveo consists of two 
components:  
1. 10 µg of lyophilized 
meningococcal serogroup A 
capsular polysaccharide 
conjugated to CRM197 (MenA) 
and  
2. 5 μg each of capsular 
polysaccharide of serogroup C, 
Y, and W135 conjugated to 
CRM197 in 0.5 mL of phosphate 
buffered saline, which is used to 
reconstitute the lyophilized MenA 
component before injection.  
 
The reconstituted vaccine should be 
used immediately. Menveo is 
administered as an intramuscular 
injection, preferably into the deltoid.  
 
 
 
 
products to alleviate vaccine wastage. 
IDPH will monitor vaccine orders to 
assure all Hib-containing vaccines 
currently in inventory will be utilized 
and not wasted. 
 
If VFC providers have questions 
regarding Hib vaccine allocations, 
please contact either Tina Patterson 
or Janean Iddings at 800-831-6293, 
extensions 4 and 5, respectively.   
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Hib Deferral for Licensed Child Care Extended 
Menveo ~ New Meningococcal Vaccine  
ACIP recommends the use of 
quadrivalent meningococcal 
conjugate vaccine for:  
 All persons 11-18 years of age  
 Persons 2-55 years of age who 
are at increased risk for 
meningococcal disease.  
 
Persons at increased risk 
for meningococcal disease 
include:  
1. College freshmen 
living in dormitories  
2. Microbiologists who 
are routinely exposed 
to isolates of Neisseria 
meningitidis  
3. Military recruits  
4. Persons who travel to 
or reside in countries 
where meningococcal 
disease is 
hyperendemic or epidemic  
5. Persons who have persistent 
complement component 
deficiencies, and  
6. Persons with anatomic or 
functional asplenia.  
 
Menveo or Menactra (conjugate 
vaccine) may be used in persons 11-
55 years of age, and are preferred to 
meningococcal polysaccharide  
vaccine (MPSV4).  
 
Persons 2-10 years of age who are 
recommended to receive a 
meningococcal vaccine (because 
they have conditions that place them 
at increased risk for meningococcal 
disease) should receive MCV4 
(Menactra), and persons older than 
55 years of age should receive 
MPSV4 (Menomune).  
 
For further information and the full 
summary please refer to the CDC 
MMWR.   
IRIS List Serve 
Subscribe to the IRIS list serve! This 
service will provide you with timely 
information regarding changes, 
maintenance or new information 
about IRIS. To subscribe, send a 
blank email message to  
join-IRISUSERS@lists.ia.gov.  
 
For questions about the IRIS list 
serve, please call the IRIS Help Desk 
at 800-374-3958.   
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Hepatitis B Birth Dose Initiative  
a 90 percent chance of becoming 
chronic carriers of hepatitis B.  Of 
those infants up to 25 percent will 
eventually develop HBV-related 
cirrhosis or cancer.  
 
Comments from newborn and labor 
& delivery personnel suggested that 
staff often delayed the birth dose 
until close to discharge and felt 
uncomfortable discussing with 
parents the importance of hepatitis B 
vaccine at birth.   
 
This campaign focuses on giving 
providers talking points to reinforce  
the importance of administering the 
hepatitis B vaccine at the same time 
as other routine medications at birth.   
 
If you would like to order posters or 
have questions regarding this 
campaign, please contact Bridget 
Konz, Perinatal Hepatitis B 
Prevention Coordinator, at 800-831-
6293, ext. 7 or at 
bkonz@idph.state.ia.us. 
The IDPH Immunization Program, in 
collaboration with the University of 
Iowa Hospitals and Clinics, has 
developed a hepatitis B birth dose 
campaign based on suggestions from 
newborn and labor and delivery 
personnel.   
 
This campaign is in response to 
recent national reports of Iowa’s 
low initiation rate of the hepatitis 
B vaccine birth dose. The 
campaign focuses on making 
the hepatitis B vaccine part of 
the routine medications 
administered at birth.  
Administering the birth dose at 
the same time as other 
medications stresses the 
importance of the hepatitis B 
vaccine immediately after birth 
and demonstrates to the 
parents the value of 
immunization for the infant.    
 
Hepatitis B remains a concern 
for infants because of their 
relatively poor ability to clear 
the infection and susceptibility to 
becoming a chronic carrier leading 
to HBV-related liver damage 
(cirrhosis) or cancer (hepatocellular 
carcinoma). Infants who are 
exposed to hepatitis B at birth have 
The Advisory Committee on 
Immunization Practices (ACIP) 
Recommends Universal 
Annual Influenza Vaccination: 
On February 24, 2010, the 
ACIP voted that everyone 6 
months and older should get a 
flu vaccine next season. 
ACIP voted for "universal" flu 
vaccination in the U.S. to 
expand protection against the 
flu to more people.  
 
Prior to the February vote, 
ACIP recommendations for seasonal 
influenza vaccination – which focused 
on vaccination of higher risk persons, 
children 6 months through 18 years 
of age and close contacts of higher 
risk persons which already applied to 
about 85 percent of the U.S. 
population.  
Discussion at the ACIP meeting 
focused on the value of protecting all 
people 19 to 49 years of age who 
have been hard hit by the 
2009 H1N1 pandemic virus, 
which is likely to continue 
circulating into next season 
and beyond. Another reason 
cited in favor of a universal 
recommendation for 
vaccination is that many 
people in currently 
recommended “higher risk” 
groups are unaware of their 
risk factors or that they are 
recommended for vaccination.  
 
The ACIP discussion also recognized 
the practicality and value of issuing a 
simple and clear message regarding 
the importance of influenza 
vaccination in the hopes that this 
would remove impediments to 
vaccination and expand coverage.  
Finally, new data collected over the 
course of the 2009 H1N1 pandemic 
indicate that some people who do 
not currently have a specific 
recommendation for vaccination 
may also be at higher risk of 
serious flu-related complications, 
including those people who are 
obese, post-partum women and 
people in certain racial/ethnic 
groups.  
 
Annual influenza vaccination is a 
safe and preventive health action 
that benefits all age groups. 
However, certain people have a 
higher risk for influenza 
complications, including people 
aged 65 years and older, children 
younger than 6 months of age, 
pregnant women, and people of 
any age with certain chronic 
medical conditions. Continued on 
page 4 
2010-2011 Influenza Season  
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2010-2011  
Influenza  
Season, cont. 
 
These people, their household and 
close contacts, and all health care 
personnel should continue to be a 
primary focus for vaccination efforts 
as providers and programs transition 
to routinely vaccinating all people 6 
months of age and older. 
 
There are three strains in the 
vaccine and next season's vaccine 
will include an A/California/7/2009 
(H1N1)-like virus, an A/
Perth/16/2009 (H3N2)-like virus, and 
a B/Brisbane/60/2008-like virus. The 
H1N1 virus recommended for 
inclusion in the 2010-2011 seasonal 
influenza vaccine is a pandemic 
2009 H1N1 virus and is the same 
virus used in the 2009 H1N1 
monovalent vaccine. 
 
Recommendations of the ACIP 
become recommendations of CDC 
once they are accepted by the 
director of CDC and the Secretary of 
Health and Human Services and are 
published in the Morbidity and 
Mortality Weekly Report.   
  
The Vaccine Adverse Event 
Reporting System (VAERS) 
VAERS is a national vaccine safety 
surveillance program co-sponsored 
by the Centers for Disease Control 
and Prevention (CDC) and the Food 
and Drug Administration (FDA).  
 
VAERS collects and analyzes 
information from reports of adverse 
events following immunization.  Very 
rarely, people experience serious 
adverse events following 
immunization. By monitoring such 
events, VAERS can help to identify 
important new safety concerns. 
 
Who can file a VAERS report? 
Anyone can submit a VAERS report. 
Most reports are sent in by vaccine 
manufacturers (42 percent) and 
health care providers (30 percent). 
The rest are submitted by state 
immunization programs (12 percent), 
vaccine recipients or their parent/
guardians (7percent), and other 
sources (9 percent). 
 
What adverse events should be 
reported? VAERS encourages the 
reporting of any clinically significant 
adverse event that occurs after the 
administration of any vaccine 
licensed in the United States. Report 
such events even if you are unsure 
whether a vaccine caused them.  
 
The National Childhood Vaccine 
Injury Act (NCVIA) requires health 
care providers to report:  
1. Any event listed by the vaccine 
manufacturer as a 
contraindication to subsequent 
doses of the vaccine. 
2. Any event listed in the 
Reportable Events Table that 
occurs within the specified time 
period after vaccination. A copy 
of the Reportable Events Table 
can be found in the PinkBook 
appendix F.  
 
Filing a VAERS report. Use a 
VAERS report form to report any 
adverse event.  Pre-addressed 
postage paid report forms  are 
available by calling VAERS at 1-800-
822-7967, or download a printable 
copy of the VAERS form from the 
following Internet sites:  
 The VAERS Web site  
 The Food and Drug 
Administration Web site 
 The CDC Web site  
Instructions are included with the 
form. A photocopy of the VAERS 
form may be used to submit a 
report. 
 
For more information: 
 Send e-mail inquiries to 
info@vaers.org 
 Visit the VAERS Web site  
 Call the toll-free VAERS 
information line at (800) 822-7967 
 Fax inquiries to the toll-free 
information fax line at (877) 721-
0366 
For information regarding VAERS at 
the Iowa Immunization program 
contact Terri Thornton 1-800-831-
6293 ext. 2. 
The Vaccine Adverse Event Reporting System  
National Infant Immunization Week 
(NIIW) is an annual observance to highlight the importance of protecting 
infants from vaccine-preventable diseases. This year NIIW will be held April 24-
May 1 and will coincide with Vaccination Week in the Americas.  
   
Any health department or immunization coalition interested in promoting infant 
immunization within their community will find abundant useful information on the CDC's NIIW Web site.  
Resources include tools for planning events and promoting them through the media; listings of NIIW activities and 
events planned across the nation; and educational materials for providers and parents.  
   
To access these NIIW resources, go to: http://www.cdc.gov/vaccines/events/niiw  
 
Vaccine Spotlight: PCV13 (Prevnar 13)   
JANUARY 2009 IMMUNIZATION UPDATE: THE IOWA IMMUNIZATION PROGRAM NEWSLETTER 
On February 24, 2010, the Food 
and Drug Administration (FDA) 
approved Pfizer’s 13-valent 
pneumococcal conjugate vaccine 
(PCV13).  PCV13 is indicated for 
active immunization of children to 
prevent invasive disease caused 
by Streptococcus pneumonia.  
 
The ACIP recommended changes 
to the immunization schedule to 
incorporate the newly approved 
vaccine by using PCV13 to 
immunize infants and toddlers, as 
well as in children 60 through 71 
months with underlying medical 
conditions that increase their risk 
of, or complications from, 
pneumococcal disease. 
 
PCV13 is also recommended as a 
supplemental dose for children 
through 59 months of age who 
have completed the age 
appropriate series of 7-valent 
pneumococcal conjugate vaccine 
(PCV7). Children who have 
started their immunization series 
with PCV7 should complete their 
series by switching to PCV13 at 
any point in the schedule.  
 
During this transition, if only PCV7 
is available in the clinic, 
unvaccinated and incompletely 
vaccinated children should receive 
PCV7. These children should 
complete the series with PCV13 at 
subsequent visits. When PCV13 is 
available in the clinic, 
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unvaccinated and incompletely 
vaccinated children should receive 
PCV13 (not PCV7) for the 
entire/complete series.  
 
Active recall is not recommended for 
children for whom the supplemental 
PCV13 dose is recommended. The 
supplemental dose should be given at 
a subsequent visit.  
 
PCV13 is now available for ordering 
through the VFC program. PCV7 
inventory in IRIS that will no longer be 
used due to the release of PCV13 
should be removed from the clinic’s 
inventory using the ‘expired’ reason 
code. Please be sure all IRIS data 
entry is up to date prior to removing 
these doses from IRIS inventory.  
 
Remaining doses of PCV7 vaccine 
should not be used once PCV13 
vaccine is available.  Unused doses of 
PCV7 vaccine should be returned to 
the VFC vaccine distributor, 
McKesson.   
 
McKesson is in the process of sending 
UPS postage paid labels to each Iowa 
VFC enrolled provider for the return of 
VFC Program purchased PCV7.  If 
your facility has not received a UPS 
postage paid label, contact Tina 
Patterson, VFC Program Coordinator 
at 800-831-6293 ext. 4 or 
tpatters@idph.state.ia.us. 
 
The VFC Nonviable Vaccine Return 
Form must be completed for all doses 
5 
of PCV7 vaccine 
that are returned to 
McKesson.  Also 
fax a copy to the 
VFC Program at 
800-831-6292 and maintain a copy for 
the clinic records. When completing 
the form it is important to include the 
reason the vaccine is being returned.  
For all PCV7 returns, utilize reason 
number 4, Expired Vaccine.   
 
In order for the Iowa VFC Program to 
receive credit for the returned 
vaccine, all unused PCV7 must be 
returned to McKesson by May 10. 
 
Pages 6 and 7 of  this newsletter 
show the ACIP recommended usage 
of PCV13 and Recommended 
Regimen for Pneumococcal 
Conjugate Vaccine Among Children 
With a Lapse in Vaccine 
Administration.   
 
For questions regarding PCV7 or 
PCV13 vaccine administration contact 
Terri or Bridget at 800-831-6293, ext 
2 and 7, respectively.   
 
For questions regarding the IRIS 
Program contact the IRIS Help Desk 
at 800-374-3958. If you have 
questions regarding the 
implementation of PCV13 call Tina 
Patterson, VFC Coordinator, at 1-800-
831-6293, ext. 4. 
To view the full MMWR click here.  
Immunization Program Welcomes New Assessment Nurses! 
The Immunization Program is proud to welcome Alison 
Monsma, RN, BA and John Fiedler, RN to the Assessment 
Program.  Alison comes from the Bureau of Family Health 
where she was the Coordinator for Discretionary Grants. John 
comes from the Bureau of EMS where he was the State Trauma Coordinator. 
Both Alison and John will be conducting quality assurance visits with VFC 
providers.  Help us welcome Alison and John! 
Alison Monsma, RN, BA  ▪  515/494-4442  ▪   amonsma@idph.state.ia.us  
John Fiedler, RN   ▪  515/954-9859▪   jfeidler@idph.state.ia.us  
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ACIP Recommended Schedule for PCV13 Vaccine 
 
Infants and children who have not previously received PCV7 or PCV13  
The ACIP recommendation for use of PCV13 and the immunization schedules for infants and toddlers 2 through 59 
months of age who have not received any prior PCV7 or PCV13 doses are the same as those previously published for 
PCV7 with PCV13 replacing PCV7 for all doses.  
Infants 2 through 6 months of age  
PCV13 is recommended as a 4-dose series at 2, 4, 6, and 12 through 15 months of age.  Infants receiving their first 
dose at less than 6 months of age should receive 3 doses of PCV13 at intervals of approximately 8 weeks (the 
minimum interval is 4 weeks). Minimum age for administration of the first dose is 6 weeks. The fourth dose is 
recommended at age 12 through 15 months and should be given at least 8 weeks after the third dose. 
 
Unvaccinated children 7 months of age and older  
Infants 7 through 11 months of age  
Three doses are recommended. The first 2 doses should be given with an interval of at least 4 weeks between doses. 
The third dose should be given at age 12 through 15 months, at least 8 weeks after the second PCV13 dose.  
Children 12 through 23 months of age  
Two doses are recommended, with an interval of at least 8 weeks between doses.  
Children 24 months of age and older  
Unvaccinated healthy children 24 through 59 months of age should receive a single dose of PCV13. Unvaccinated 
children 24 through 71 months of age with underlying medical conditions should receive 2 doses of PCV13 with an 
interval of at least 8 weeks between doses.  
 
Children incompletely vaccinated with PCV7 or PCV13  
Children less than 24 months of age  
Infants and children less than 24 months of age who have received one or more doses of PCV7 should complete the 
immunization series with PCV13.  
Children greater than 24 months of age  
A single dose of PCV13 is recommended for all healthy children 24 through 59 months of age with any incomplete 
PCV schedule (PCV7 or PCV13).   
For children 24 through 71 months of age with underlying medical conditions who have received any incomplete 
schedule of less than 3 doses of PCV (PCV7 or PCV13), 2 doses of PCV13 are recommended. For children with 
underlying medical conditions who have received 3 doses of PCV (PCV7 or PCV13), a single dose of PCV13 is 
recommended through 71 months of age.  
The minimum interval between doses is 8 weeks.  
 
Children completely vaccinated with PCV7  
A single supplemental dose of PCV13 is recommended for all children 14 through 59 months of age who have 
received 4 doses of PCV7 or other age-appropriate, complete PCV7 series (fully vaccinated with PCV7).   
For children who have underlying medical conditions, a single supplemental PCV13 dose is recommended through 71 
months of age. This includes children who have previously received the 23-valent pneumococcal polysaccharide 
vaccine (PPSV23).  PCV13 should be given at least 8 weeks after the last dose of PCV7 or PPSV23.  
 
Children 6 through 18 years of age with high-risk conditions  
A single dose of PCV13 may be administered to children 6 through 18 years of age who are at increased risk for 
invasive pneumococcal disease because of sickle cell disease, HIV-infection or other immunocompromising condition, 
cochlear implant or cerebrospinal fluid leaks, regardless of whether they have previously received PCV7 or PPSV23.  
 
Use of PPSV23 among children 2 through 18 years of age who are at increased risk for invasive 
pneumococcal disease  
In addition to receiving PCV13, children with underlying medical conditions should receive PPSV23 at age 2 years or 
as soon as possible after the diagnosis of chronic illness is made in children 2 years of age or older.  Doses of PCV13 
should be completed before PPSV23 is given.  The minimum interval is at least 8 weeks after the last dose of PCV13.  
However, children who have previously received PPSV23 should also receive the recommended PCV13 doses.  
A second dose of PPSV23 is recommended 5 years after the first dose of PPSV23 for children who have sickle cell 
disease, functional or anatomic asplenia, HIV-infection, or other immunocompromising condition.  No more than two 
PPSV23 doses are recommended.  
Recommended Regimen for Pneumococcal Conjugate Vaccine 
Among Children With a Lapse in Vaccine Administration 
 
How to use this chart: 
1. Locate the child’s age in the left column. 
2. In the row with the child’s age, locate the number of previous doses of PCV received. 
3. The corresponding cell to the right of the number of previous doses in the “recommended regimen” column provides the 
recommended number of doses for the child.  
 
 Infants and children who began the pneumococcal series with PCV7 may complete the series by switching to PCV13 at any point 
in the immunization schedule. 
 
 Children who have completed a series with PCV7 (4 doses of PCV7 or other age-appropriate complete PCV7 schedule) should 
receive a single dose of PCV13, 2 months following the prior dose.  This dose should not be given after 59 months of age.   
 
 Vaccine recommendations for children with underlying medical conditions or increased risk for invasive pneumococcal disease is 
available in the Morbidity and Mortality Weekly Report (MMWR), Licensure of a 13-Valent Pneumococcal Conjugate 
Vaccine (PCV13) and Recommendations for Use Among Children, Advisory Committee on Immunization 
Practices (ACIP), 2010 available by clicking here.   
            Rev: 3-11-2010 
Child’s age now Previous pneumococcal   conjugate vaccination Recommended regimen 
Total doses 
in the series 
2 through 6 
months 
0 doses Give 3 doses 2 months apart. The 4th dose will be given at 12-15 months as the final dose 4 
1 dose Give 2 doses 2 months apart. The 4th dose will be given at 12-15 months as the final dose 4 
2 doses Give 1 dose. The 4th dose will be given at 12-15 months as the final dose 4 
7 through 11 
months 
0 doses Give 2 doses 2 months apart, 3rd dose at 12-15 months as the final dose 3 
1 or 2 doses before age 7 months 
Give 1 dose at 7-11 months, with another dose 
at 12-15 months (> 2 months later)  as the 
final dose 
3 or 4 
12 through 23 
months 
0 doses Give 2 doses > 2 months apart as the final 2 
1 dose before age 12 months Give 2 doses > 2 months apart as the final dose 3 
2 doses before age 12 months Give 1 dose > 2 months after the most recent dose as the final dose 3 
1 dose on or after age 12 months Give 1 dose > 2 months after the most recent dose as the final dose 2 
  
24 through 59 
months 
  
  
No previous doses Give one dose as the single and final dose. 1 
If 1, 2 or 3 doses before 12 months Give 1 dose > 2 months after the most recent dose as the final dose 2,3, or 4 
If 1 dose between 12-23 months Give 1 dose > 2 months after the most recent dose as the final dose 2 
If 2 doses between 12-23 months No additional doses.  Child is complete. 2 
If 1, 2, or 3 doses before 12 months 
and 1 dose between 12-23 months 
(separated by at least 2 months) 
No additional doses.  Child is complete. 2,3, or 4 
If 1 dose after 24 months No additional doses.  Child is complete. 1 
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